Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80,080 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab.
Liu X, Fridman JS, Wang Q, Caulder E, Yang G, Covington M, Liu C, Marando C, Zhuo J, Li Y, Yao W, Vaddi K, Newton RC, Scherle PA, Friedman SM. Liu X, et al. Among authors: liu c. Cancer Biol Ther. 2006 Jun;5(6):648-56. doi: 10.4161/cbt.5.6.2707. Epub 2006 Jun 14. Cancer Biol Ther. 2006. PMID: 16627988 Free article.
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.
Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E, Lo Y, Baribaud F, Mikami I, Reguart N, Yang G, Li Y, Yao W, Vaddi K, Gazdar AF, Friedman SM, Jablons DM, Newton RC, Fridman JS, Minna JD, Scherle PA. Zhou BB, et al. Among authors: liu c. Cancer Cell. 2006 Jul;10(1):39-50. doi: 10.1016/j.ccr.2006.05.024. Cancer Cell. 2006. PMID: 16843264 Free PMC article.
Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.
Yao W, Zhuo J, Burns DM, Xu M, Zhang C, Li YL, Qian DQ, He C, Weng L, Shi E, Lin Q, Agrios C, Burn TC, Caulder E, Covington MB, Fridman JS, Friedman S, Katiyar K, Hollis G, Li Y, Liu C, Liu X, Marando CA, Newton R, Pan M, Scherle P, Taylor N, Vaddi K, Wasserman ZR, Wynn R, Yeleswaram S, Jalluri R, Bower M, Zhou BB, Metcalf B. Yao W, et al. Among authors: liu x, liu c. J Med Chem. 2007 Feb 22;50(4):603-6. doi: 10.1021/jm061344o. Epub 2007 Jan 26. J Med Chem. 2007. PMID: 17256836
Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model.
Yue EW, Douty B, Wayland B, Bower M, Liu X, Leffet L, Wang Q, Bowman KJ, Hansbury MJ, Liu C, Wei M, Li Y, Wynn R, Burn TC, Koblish HK, Fridman JS, Metcalf B, Scherle PA, Combs AP. Yue EW, et al. Among authors: liu x, liu c. J Med Chem. 2009 Dec 10;52(23):7364-7. doi: 10.1021/jm900518f. J Med Chem. 2009. PMID: 19507862
Receptor CDCP1 is a potential target for personalized imaging and treatment of poor outcome HER2+, triple negative and metastatic ER+/HER2- breast cancers.
Gough M, Kwah KK, Khan T, Ghosh S, Sun B, Lee CY, Sokolowski KA, Tse BW, Wickramasuriya L, Ferguson K, Rogers R, Goh JB, Fletcher NL, Houston ZH, Thurecht KJ, Bray LJ, Liu C, Pyke C, Lim E, Snell CE, He Y, Hooper JD, Kryza T. Gough M, et al. Among authors: liu c. Clin Cancer Res. 2025 Jan 27. doi: 10.1158/1078-0432.CCR-24-2865. Online ahead of print. Clin Cancer Res. 2025. PMID: 39869307
80,080 results
You have reached the last available page of results. Please see the User Guide for more information.